Creatine on a GLP-1: The Trial Nobody Has Run

Creatine monohydrate is the most-studied supplement in sports nutrition, and the question of whether it protects muscle while a GLP‑1 strips weight off you has never been tested. The 2026 review that surveyed this whole field puts creatine among the options “supported mainly by indirect or phenotype-specific evidence,” meaning the evidence comes from people who were not taking these drugs.^[1] Everything below argues from adjacent trials, and some parts of that argument are stronger than others.

What has actually been measured

The closest evidence is a 12-week randomized trial published in 2026. Sixty-four adults aged 45 to 65 completed it, taking either 2×5 g a day of creatine monohydrate or a maltodextrin placebo, double-blind, with body composition measured by DXA at 0, 6 and 12 weeks. Among those doing an exercise and weight-loss diet program, creatine increased lean tissue mass, produced a greater reduction in body fat percentage, and improved muscular strength and endurance. Among those not exercising or dieting, it still increased lean tissue mass, strength and muscular endurance.^[3]

Nobody in that trial was taking a GLP‑1. That gap is large. These drugs cut total energy and protein intake in a way that a voluntary diet does not, and much of the case for creatine assumes adequate protein and a training stimulus are already in place. How much lean mass goes on these drugs, and how it compares with dieting without them, is measured in hair loss and muscle loss on a GLP-1.

What creatine is being asked to fix is larger than most coverage admits. A 2025 review of nutrition support during GLP‑1 therapy reports that up to 40% of total weight loss can come from fat-free mass, while noting that fat-free mass includes non-muscle components. It is cautious about the countermeasures: resistance training and adequate protein intake can mitigate muscle loss, “but the evidence for their efficacy in the context of GLP-1 RA therapy is mixed.” Creatine appears there only conditionally, among nutrients that may be beneficial if training and protein prove insufficient.^[4]

Why the reasoning is still respectable

A 2025 narrative review of supplements during GLP‑1 receptor agonist treatment reaches the most specific statement available on the question. Its finding is conditional, and the conditions matter. When combined with resistance training, whey protein can help preserve lean body mass during weight loss, “with additional strength benefits from creatine monohydrate and β-Hydroxy β-Methylbutyrate supplementation.” The same review puts daily protein intake at 1.2 to 2.0 g per kilogram of body weight.^[2]

Note the order of operations in that sentence. Resistance training is the condition, protein is the base, and creatine is described as an addition on top of both. The benefit it names is strength, not lean mass. Nothing in it supports creatine as a substitute for either of the two things it is added to. What that protein base looks like in practice, and the blood work worth watching alongside it, is set out in protein targets and the lab panel; if little or none of your protein is coming from animal sources, plant-based protein on a GLP-1 covers why the daily total has to go higher.

The measurement problem nobody mentions

This changes how you should read any number in this area. The 2026 review is blunt that DXA-derived lean mass and bioimpedance-derived fat-free mass “are not equivalent to skeletal muscle, and lean tissue loss does not necessarily indicate impaired strength or physical performance.”^[1] Those scans measure a compartment that includes water. How the result is expressed matters as well: in a compounded semaglutide study, the lean share of body mass rose even though 35% of the weight lost was lean tissue.

Creatine loading increases the water held inside muscle cells. That is a real physiological effect and it is also, unavoidably, a change in the thing the scan counts. So a creatine user can post a better lean-mass number without that number telling you what happened to their muscle. When a supplement page quotes a lean-mass delta at you and does not raise this, it is quoting a scale reading as though it were an outcome.

What would settle it

It would take a trial of creatine in people starting a GLP‑1 that measures strength and physical function, not lean mass alone. Searching the clinical trials register on August 31, 2026 turned up no such completed study. The nearest registered work, NCT07760948, tests HMB plus vitamin D in older adults starting semaglutide, and had not begun recruiting. Drugs meant to protect muscle are in trials, bimagrumab alongside semaglutide among them, but creatine has no such trial yet.

Until that exists, the case for creatine is narrow. A drug built specifically to hold muscle during weight loss, bimagrumab, has been through trials, and reading what it took to demonstrate that is a useful calibration for how much a supplement should be expected to do. Creatine has a long safety record and a large evidence base for strength in trained and untrained adults. It has no evidence base in people on these drugs, its most-cited benefit here is strength rather than muscle mass, and the measurement most often used to sell it is one it directly inflates. Whether that adds up to worth taking is a question for the person prescribing your medication, who knows your kidney function and what else you are on.